Quick Order Cart

Cat. No. ARG43699

ACSL5 Knockout HuH-7 Cell Line

  • Product Type:

    In Stock Cell Lines

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Liver

  • Disease:

    Hepatocellular carcinoma

The ACSL5 Knockout HuH-7 Cell Line is a CRISPR/Cas9-edited knockout cell line engineered to disrupt ACSL5 in HuH-7 human hepatocellular carcinoma cells. ACSL5 encodes a long-chain fatty acyl-CoA synthetase critical for fatty acid activation, channeling lipids into ??-oxidation, triglyceride synthesis, and phospholipid production. It is regulated by PPAR?? and SREBP-1c and interacts with FATP2 and lipid droplet proteins. This knockout model impairs lipid metabolism, making it valuable for studying hepatic steatosis, hepatocellular carcinoma, and metabolic disorders. Suitable for assays including lipidomics, Oil Red O staining, and mitochondrial respiration measurements.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    Huh-7

    Sex of Donor

    Male

    Age

    57 years

    Gene Name

    ACSL5

    Gene Identifier

    NCBI Gene ID 51703

    Morphology

    Epithelial-like

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% COâ‚‚

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The ACSL5 Knockout HuH-7 Cell Line is a CRISPR/Cas9-edited knockout cell line that disrupts the ACSL5 gene in HuH-7 human hepatocellular carcinoma cells. This loss-of-function model enables stable and reproducible ablation of ACSL5 expression, facilitating detailed investigation of fatty acid metabolism and lipid signaling pathways in a hepatic context.

HuH-7 cells originate from a well-differentiated hepatocellular carcinoma of a 57-year-old male and retain liver-specific functions, making them an ideal model for liver cancer, hepatocyte metabolism, and viral hepatitis research. Their metabolic competence supports physiologically relevant studies of hepatic lipid handling, providing a robust background for interrogating ACSL5 function.

ACSL5 encodes a long-chain fatty acyl-CoA synthetase that catalyzes the thioesterification of fatty acids with coenzyme A, a critical activation step. It is transcriptionally regulated by PPAR??, SREBP-1c, ChREBP, and LXR, and responds to insulin, glucose, and polyunsaturated fatty acids. The resulting acyl-CoAs are directed to CPT1A for ??-oxidation, DGAT1/2 for triglyceride synthesis, and phospholipid biosynthetic enzymes, also contributing to pro-inflammatory eicosanoids. ACSL5 interacts with fatty acid transporters FATP2/4, lipid droplet proteins, and MBOAT7, and operates upstream of PPAR?? transcriptional programs controlling lipid catabolism and energy homeostasis.

In HuH-7 cells, ACSL5 disruption impairs fatty acid activation, reducing acyl-CoA pools. This compromises triglyceride and phospholipid synthesis, attenuates fatty acid oxidation, and dampens PPAR?? signaling. Consequently, the knockout model often exhibits reduced lipid accumulation, altered membrane composition, and modified cell proliferation??phenotypes relevant to hepatic steatosis, hepatocellular carcinoma, and metabolic syndrome. Thus, it serves as a powerful tool for dissecting lipid metabolic dysfunction.

This cell line supports diverse applications: mechanistic studies of lipid metabolism in liver cancer, lipid droplet dynamics, and drug screening for NAFLD. It is suitable for Western blotting, RT-qPCR, fatty acid oxidation assays, triglyceride quantification, Oil Red O staining, lipidomics, Seahorse respiration analysis, and flow cytometry. The model also enables transcriptomic and interactome studies to elucidate ACSL5-dependent networks. For further details, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)